Risk-adjustment models for heart failure patients’ 30-day mortality and readmission rates: the incremental value of clinical data abstracted from medical charts beyond hospital discharge record by unknown
Lenzi et al. BMC Health Services Research  (2016) 16:473 
DOI 10.1186/s12913-016-1731-9RESEARCH ARTICLE Open AccessRisk-adjustment models for heart failure
patients’ 30-day mortality and readmission
rates: the incremental value of clinical data
abstracted from medical charts beyond
hospital discharge record
Jacopo Lenzi1†, Vera Maria Avaldi1†, Tina Hernandez-Boussard2, Carlo Descovich3, Ilaria Castaldini4,
Stefano Urbinati5, Giuseppe Di Pasquale6, Paola Rucci1 and Maria Pia Fantini1*Abstract
Background: Hospital discharge records (HDRs) are routinely used to assess outcomes of care and to compare
hospital performance for heart failure. The advantages of using clinical data from medical charts to improve
risk-adjustment models remain controversial. The aim of the present study was to evaluate the additional
contribution of clinical variables to HDR-based 30-day mortality and readmission models in patients with
heart failure.
Methods: This retrospective observational study included all patients residing in the Local Healthcare Authority of
Bologna (about 1 million inhabitants) who were discharged in 2012 from one of three hospitals in the area with a
diagnosis of heart failure. For each study outcome, we compared the discrimination of the two risk-adjustment
models (i.e., HDR-only model and HDR-clinical model) through the area under the ROC curve (AUC).
Results: A total of 1145 and 1025 patients were included in the mortality and readmission analyses, respectively.
Adding clinical data significantly improved the discrimination of the mortality model (AUC = 0.84 vs. 0.73, p < 0.001),
but not the discrimination of the readmission model (AUC = 0.65 vs. 0.63, p = 0.08).
Conclusions: We identified clinical variables that significantly improved the discrimination of the HDR-only model
for 30-day mortality following heart failure. By contrast, clinical variables made little contribution to the
discrimination of the HDR-only model for 30-day readmission.
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Heart failure (HF) is a complex syndrome characterized
by high mortality and morbidity and is a leading cause
of hospitalization [1]. Aging population, decreased HF
mortality due to improvement of therapeutic interven-
tions, effective secondary prevention, and hospital and
primary care management strategies have led to an
increased burden of HF on healthcare systems [1, 2].
Assessing quality of care, especially outcomes of care,
and comparing hospital performance have become
important issues needed to ensure a healthcare system
that is cost-effective for HF [3, 4]. To this end, statistical
models to compare hospital performance across import-
ant outcomes must adjust for differences in demo-
graphic and clinical characteristics, as the case mix of
patients may vary among regions and hospitals [5, 6].
Hospital discharge records (HDRs) (also known as ad-
ministrative claims databases) are a main source of data
for outcomes studies because data collection is inexpen-
sive and they enable the analysis of large populations
and a large number of conditions and pathologies [7];
however, these data lack clinical granularity and do not
allow one to determine the severity and history of
disease [5–8]. In Italy, the National Outcome Evaluation
Program (Programma Nazionale Esiti – PNE), an initia-
tive endorsed by the National Agency for Regional
Health Services (Agenzia Nazionale per i Servizi Sanitari
Regionali–AGENAS) that monitors healthcare outcomes
across hospitals and municipalities, routinely uses HDRs
to derive hospital-specific indicators and important
patient characteristics used in risk-adjustment of differ-
ent patient populations [9].
Many authors have underlined the advantages of adding
specific clinical data to HDR-based risk-adjustment
models [8, 10–13]: the integration of clinical data with
HDRs in risk-adjustment models could improve the
predictive power and the control of confounding, and
identify variables that mainly influence the outcome [13].
Medical charts could indeed offer important information
on the patient’s clinical conditions unavailable in HDRs
that allow one to differentiate between comorbidities and
complications [8].
With regard to HF, a recent study [14] suggested that the
addition of clinical data to HDR-based models improved
the discrimination of mortality risk-adjustment models and
shifted mortality performance rankings in inter-hospital
comparison. However, clinical data did not substantially
improve the discrimination of the readmission risk model
nor the hospital ranking. Another study [5] found no differ-
ence between HDR- and clinical-based predictive models
for 30-day mortality. Overall, a recent systematic review of
the literature revealed that the discriminatory ability of the
models was generally higher for the prediction of death
than for the prediction of hospital readmission [15].The impact of clinical data in risk-adjustment models
is therefore controversial because, even though clinical
data add information, they do not always improve the
discrimination of the models. Moreover, the availability
and reliability of clinical data may vary greatly among
hospitals, and their collection entails more effort and
costs than HDRs data. For this reason, it is useful to
identify a limited number of clinical variables that are
significantly correlated with HF outcomes and are
affordable and easy to collect [7]. The aim of this study
was to evaluate the usefulness of clinical variables and
drug prescriptions in predicting 30-day mortality and
30-day readmissions in patients with HF.
Methods
Setting and study population
This retrospective observational study included all
patients residing in the Local Healthcare Authority
(LHA) of Bologna who were discharged from one of
three public hospitals in the area (hereinafter called “A”,
“B” and “C”) between December 2, 2011 and December
1, 2012 with a primary diagnosis of HF (ICD-9-CM diag-
nosis codes: 398.91, 402.x1, 404.x1, 404.x3, 428.xx). Data
were retrieved from the HDRs Database (see Additional
file 1 for a description of the data source).
Hospital A is the second largest hospital of Bologna,
with more than 900 beds and about 40 wards; hospital
B, also located in Bologna, has about 370 bed and 20
wards, and is a center of excellence in the field of
neuroscience; hospital C is located in a municipality not
far from Bologna, with about 200 beds and 15 wards,
and is the referral facility in the northern LHA area.
Patients were excluded if any of the following criteria
were met:
1. A secondary diagnosis of non-cardiogenic acute
pulmonary edema or acute kidney failure (ICD-9-CM
diagnosis codes: 518.4, 584.x), i.e., patients with
symptoms probably related to causes other than HF,
in keeping with the PNE definition to allow
comparison of results;
2. Age <18 or >100 years, because very young and very
old patients may have distinctive clinical features at
diagnosis and survival;
3. Transfer from another facility, to ascribe the study
outcomes to the hospital where the patient was
initially admitted;
4. Incomplete clinical data (i.e., missing laboratory
data, electrocardiography, etc.), to ensure
comparability of risk-adjustment models. We
decided to exclude these patients because the
pattern of missing clinical data appeared to be
independent of patient’s age, gender and length of
stay (data not shown).
Lenzi et al. BMC Health Services Research  (2016) 16:473 Page 3 of 12For patients with multiple eligible hospital admissions
over the 1-year study period, we considered only the first
one as the index admission because hospitalizations of the
same patient are correlated, thus violating the assumption
of independence required by regression models. Still, we
are aware that excluding multiple readmissions, i.e.,
hospital admissions of patients with presumably chronic
HF, may limit the generalizability of the results.
Data
Variables considered for inclusion in risk-adjustment
models were retrieved from three data sources: (1)
HDRs, (2) Outpatient Pharmaceutical Database (OPD),
and (3) medical charts (see Additional file 1 for a
description of the data sources).
Variables retrieved from the HDRs Database were: age,
gender, length of stay, and 23 comorbidities chosen a
priori and identified in the index hospitalization and in all
hospital admissions occurring two-years prior to the index
hospitalization (see Additional file 2, which includes the
detailed list of comorbidities). Moreover, we collected
from the OPD information on filled prescriptions of: anti-
diabetic drugs (ATC code A10), drugs for cardiac therapy
(C01), drugs for obstructive airway diseases (R03),
diuretics (C03), β-blockers (C07), angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers (C09),
calcium channel blockers and/or other antihypertensive
drugs (C08, C02), statins (C10AA), and antiplatelet drugs
(B01AC). Treatment for each drug was defined as at least
one filled prescription in the three months preceding the
HF hospital admission.
Clinical data abstracted from medical chart review
were:
1. Emergency department utilization (yes/no);
2. Heart rate (bpm) and systolic blood pressure
(mmHg) at hospital admission;
3. Pulmonary congestion (yes/no), determined with
radiography at hospital admission;
4. Heart rhythm (sinus rhythm/atrial fibrillation/
pacemaker rhythm), bundle branch block (no/right/
left), and QRS complex (only for patients with left
bundle branch block) retrieved from
electrocardiography at hospital admission;
5. Serum creatinine (mg/dL), sodium (mmol/L), and
hemoglobin (g/dL) at hospital admission;
6. Previously implanted cardiac devices, including
cardiac resynchronization therapies (yes/no):
pacemaker, implantable cardioverter defibrillator
(ICD).
We selected these clinical data for three main reasons.
First, other studies have shown that these data are pre-
dictive of mortality and/or readmission among patientswith HF [15–21]. Second, most of these measures are
quantitative measures that are not captured in HDRs.
Lastly these data reflect multiple clinical domains,
including laboratory test results, diagnostic test results
and vital signs.
The data collection for the present study consisted of
a thorough review of more than 1000 medical charts
which, in Emilia-Romagna, are still paper-based. This
review process was carried out by four medical residents
in Public Health who had been previously trained by a
team of cardiologists. The objective of this training was
to test and improve the review of medical charts, and to
ensure that medical residents would collect only clinical
data determined at hospital admission, i.e., prior to any
medical intervention. Medical residents worked always
in pairs and imputed data abstracted from medical
charts in a spreadsheet which was later linked with
HDRs and OPD using the patient’s identification code.
Study outcomes
The study had two main outcomes of interest. The first
outcome was all-cause death within thirty days of index
admission, identified through the Regional Mortality
Register Database (see Additional file 1 for a description
of the data source). The second outcome of interest was
all-cause unplanned readmission to any Italian hospital
between two to thirty days after the index discharge and
lasting more than one day. For the readmission analysis we
excluded patients deceased during index hospitalization, as
they cannot experience rehospitalizations.
Statistical analysis
Analysis of variance, Kruskal-Wallis test, χ2 test and
Fisher’s exact test were used, where appropriate, to com-
pare the distribution of patients’ demographic and
clinical characteristics across hospitals.
Risk-adjustment models based on HDR variables
The crude association between each potential predictor
and the study outcomes (30-day mortality and
unplanned readmissions) was first examined in univari-
able logistic regression models. In these models, age and
length of stay were transformed into normally distrib-
uted variables (cubed and log-transformed, respectively)
in order to linearize their relationship with the logistic
link function [22]. Predictors significantly associated
with the outcome at p <0.25 in univariable analyses were
selected for inclusion in multivariable logistic regression
models. A bootstrap procedure was used to determine
which of these factors were significantly associated with
the outcome in multivariable models. Using this ap-
proach, 1000 replicated bootstrap samples were selected
from the original cohort. In each replicated sample, age
and gender were forced into the model, and a backward
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significance level of removal equal to 0.05. Only risk
factors selected in at least 50 % of the replicates were
included as covariates in the final multivariable logistic
regression models.Risk-adjustment models based on HDR plus OPD plus
medical charts variables
The steps described above to build the HDR-only model
were replicated by adding the variables retrieved from
OPD and medical charts to HRD variables. Systolic
blood pressure was log-transformed and serum creatin-
ine was transformed using the reciprocal of square root
to normalize their distribution.
For each study outcome, we compared the discrimin-
ation of the two risk-adjustment models through the
area under the ROC curve (AUC). Discrimination is the
ability of the model to distinguish between high-risk and
low-risk patients. The incremental contribution of the
variables retrieved from OPD plus medical charts was
assessed also using the likelihood ratio (LR) test, because
it has been demonstrated that the AUC test produces
conservative test size and low power [23]. Lastly, the
goodness of fit of each model was estimated using the
coefficient of determination (McFadden’s adjusted
pseudo R2) and the Akaike Information Criterion (AIC).
Statistical analyses were carried out using the Stata
software package, version 13 (StataCorp. 2013. Stata
Statistical Software: Release 13. College Station, TX:
StataCorp LP).Fig. 1 Patients’ flow diagramResults
Of the 1334 patients discharged after HF, 1145 (85.8 %)
met inclusion criteria for the mortality analyses, while
1025 (76.8 %) met inclusion criteria for the readmission
analyses (Fig. 1). The overall 30-day mortality and 30-day
readmission rates were 13.2 % (151 patients out of 1145)
and 15.6 % (160 patients out of 1025), respectively. Of the
151 deaths within 30 days of hospital admission, 15
(9.9 %) occurred on the day of admission, and 37 (24.5 %)
occurred after hospital discharge. Of the 160 patients
rehospitalized within 30 days of discharge, 55 (34.4 %)
were readmitted to the hospital for another episode of HF,
and 21 (13.1 %) for cardiovascular causes other than HF.
The crude 30-day mortality rates in hospitals A, B and C
were 16.0, 2.1 and 8.7 %, while the crude 30-day readmis-
sion rates were 15.2, 24.2 and 13.5 %, respectively.
The distribution of patient characteristics, overall and
by hospital, is reported in Table 1. Mean age was
81 years, 54.3 % were female, and median length of stay
was 7 days. The most frequent comorbid conditions
were hypertension (32.7 %), other forms of ischemic
heart disease (32.4 %), previous HF diagnosis (28.9 %),
conduction disorders and cardiac dysrhythmias (27.7 %),
and chronic nephropathies (26.6 %). Mean heart rate
and systolic blood pressure were 87 ± 20.2 bpm and 140 ±
32.6 mmHg, respectively. Almost two thirds of patients
(60.7 %) had used calcium channel blockers and/or other
antihypertensive drugs before admission. Some differences
in the case mix of patients discharged from the three
hospitals were found; specifically, patients from hospital A
were older and more frequently female, and had more
Table 1 Distribution of patient characteristics collected from HDRs, OPD and medical charts, overall and by hospital
Patient characteristics Hospital A Hospital B Hospital C All p
(n = 786) (n = 96) (n = 263) (n = 1145)
From HDRs
Age in years, mean [SD] 82.3 [9.2] 77.1 [11.0] 79.7 [10.2] 81.3 [9.8] <0.001
Gender, n (%) 0.01
Male 339 (43.1) 55 (57.3) 129 (49.0) 523 (45.7)
Female 447 (56.9) 41 (42.7) 134 (51.0) 622 (54.3)
Length of stay in days, median [IQR] 8 [7] 9.5 [9.5] 8 [6] 8 [7] <0.001
Comorbidity, n (%)
Malignant tumors 75 (9.5) 11 (11.5) 31 (11.8) 117 (10.2) 0.53
Diabetes 129 (16.4) 19 (19.8) 49 (18.6) 197 (17.2) 0.56
Disorders of lipoid metabolism 44 (5.6) 6 (6.3) 27 (10.3) 77 (6.7) 0.03
Obesity 23 (2.9) 2 (2.1) 13 (4.9) 38 (3.3) 0.26
Hematologic diseases 127 (16.2) 10 (10.4) 50 (19.0) 187 (16.3) 0.14
Hypertensive diseases 247 (31.4) 31 (32.3) 96 (36.5) 374 (32.7) 0.31
Previous AMI 122 (15.5) 25 (26.0) 48 (18.3) 195 (17.0) 0.03
Other forms of ischemic heart disease 257 (32.7) 42 (43.8) 72 (27.4) 371 (32.4) 0.01
Ill-defined descriptions and complications of heart disease 12 (1.5) 4 (4.2) 6 (2.3) 22 (1.9) 0.14
Rheumatic heart disease 50 (6.4) 9 (9.4) 15 (5.7) 74 (6.5) 0.45
Cardiomyopathies 56 (7.1) 21 (21.9) 19 (7.2) 96 (8.4) <0.001
Other cardiac diseases 60 (7.6) 21 (21.9) 34 (12.9) 115 (10.0) <0.001
Conduction disorders and cardiac dysrhythmias 207 (26.3) 30 (31.3) 80 (30.4) 317 (27.7) 0.32
Cerebrovascular diseases 121 (15.4) 21 (21.9) 50 (19.0) 192 (16.8) 0.15
Vascular diseases 66 (8.4) 11 (11.5) 26 (9.9) 103 (9.0) 0.52
COPD 122 (15.5) 19 (19.8) 42 (16.0) 183 (16.0) 0.56
Chronic nephropathies 173 (22.0) 34 (35.4) 97 (36.9) 304 (26.6) <0.001
Chronic diseases of liver, pancreas and intestine 16 (2.0) 1 (1.0) 5 (1.9) 22 (1.9) >0.99
Previous bypass 14 (1.8) 6 (6.3) 18 (6.8) 38 (3.3) <0.001
Previous PCI 40 (5.1) 9 (9.4) 16 (6.1) 65 (5.7) 0.20
Other surgery of the heart 18 (2.3) 9 (9.4) 7 (2.7) 34 (3.0) <0.01
Other surgery of great vessels 18 (2.3) 2 (2.1) 8 (3.0) 28 (2.4) 0.74
Previous diagnosis of heart failure 223 (28.4) 34 (35.4) 74 (28.1) 331 (28.9) 0.34
From OPD
Previous medication use, n (%)
Antidiabetic drugs 174 (22.1) 24 (25.0) 59 (22.4) 257 (22.4) 0.79
Drugs for cardiac therapy 262 (33.3) 25 (26.0) 70 (26.6) 357 (31.2) 0.07
Drugs for obstructive airway diseases 163 (20.7) 30 (31.3) 70 (26.6) 263 (23.0) 0.02
Diuretics 457 (58.1) 59 (61.5) 159 (60.5) 675 (59.0) 0.70
β-blockers 200 (25.4) 32 (33.3) 75 (28.5) 307 (26.8) 0.20
ACEIs/ARBs 366 (46.6) 38 (39.6) 115 (43.7) 519 (45.3) 0.36
Calcium channel blockers and/or other antihypertensive drugs 472 (60.1) 68 (70.8) 155 (58.9) 695 (60.7) 0.10
Statins 383 (48.7) 53 (55.2) 131 (49.8) 567 (49.5) 0.49
Antiplatelet drugs 181 (23.0) 25 (26.0) 56 (21.3) 262 (22.9) 0.63
From medical charts
Emergency department utilization, n (%) 767 (97.6) 78 (81.3) 256 (97.3) 1101 (96.2) <0.001
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Table 1 Distribution of patient characteristics collected from HDRs, OPD and medical charts, overall and by hospital (Continued)
Heart rate in bpm, mean [SD]a 87 [20.7] 86 [19.4] 85 [18.7] 87 [20.2] 0.52
Systolic blood pressure in mmHg, mean [SD] 140 [32.8] 139 [32.5] 142 [32.3] 140 [32.6] 0.67
Pulmonary congestion, n (%) 666 (84.7) 87 (90.6) 241 (91.6) 994 (86.8) <0.001
Heart rhythm, n (%) 0.14
Sinus rhythm 405 (51.5) 42 (43.8) 127 (48.3) 574 (50.1)
Atrial fibrillation 323 (41.1) 41 (42.7) 118 (44.9) 482 (42.1)
Pacemaker rhythm 55 (7.0) 13 (13.5) 18 (6.8) 86 (7.5)
Bundle branch block, n (%) 0.55
No 625 (79.5) 78 (81.3) 208 (79.1) 911 (79.6)
Right 72 (9.2) 6 (6.3) 30 (11.4) 108 (9.4)
Left 89 (11.3) 12 (12.5) 25 (9.5) 126 (11.0)
QRS complex, mean [SD]b 151 [18.1] 159 [24.0] 152 [19.9] 152 [19.0] 0.25
Serum creatinine in mg/dL, mean [SD] 1.42 [0.9] 1.32 [0.6] 1.4 [0.9] 1.41 [0.9] 0.59
Chronic kidney disease stage (using MDRD formula), n (%) 0.38
1 60 (7.6) 9 (9.4) 32 (12.2) 101 (8.8)
2 210 (26.7) 25 (26.0) 74 (28.1) 309 (27.0)
3a 191 (24.3) 24 (25.0) 53 (20.2) 268 (23.4)
3b 179 (22.8) 27 (28.1) 60 (22.8) 266 (23.2)
4 122 (15.5) 10 (10.4) 35 (13.3) 167 (14.6)
5 24 (3.1) 1 (1.0) 9 (3.4) 34 (3.0)
Sodium in mmol/l, mean [SD] 139 [5.8] 139 [3.7] 138 [4.8] 139 [5.4] <0.001
Hemoglobin in g/dL, mean [SD] 12.1 [2.2] 12.1 [1.9] 12.1 [2.0] 12.1 [2.1] >0.90
Previously implanted pacemaker, n (%) 80 (10.2) 21 (21.9) 29 (11.0) 130 (11.4) <0.01
Previously implanted cardioverter defibrillator, n (%) 13 (1.7) 10 (10.4) 9 (3.4) 32 (2.8) <0.001
Abbreviations: HDR Hospital Discharge Record, SD standard deviation, IQR interquartile range, AMI acute myocardial infarction, COPD chronic obstructive pulmonary
disease, PCI percutaneous coronary intervention, OPD Outpatient Pharmaceutical Database, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker, MDRD Modification of Diet in Renal Disease
aOnly for patients with sinus rhythm
bOnly for patients with left bundle branch block
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congestion; on the other hand, patients discharged from
hospital B had more cardiovascular comorbidities and
previous device implantation, and used less frequently
emergency department.
Comparison of risk-adjustment models
Table 2 reports the variables retained in the risk-
adjustment models based on HDRs only (models #1)
and HDR plus clinical data (models #2). Figure 2 illus-
trates, for each of the continuous variables retained in
models #2, the predicted probabilities of death and
readmission.
Thirty-day mortality
The probability of 30-day mortality started increasing
after the age of 70-80, with no gender differences. Of the
HDR variables, only cerebrovascular disease was in-
cluded in the final model (odds ratio = 1.96, p < 0.001).
Of the variables retrieved from medical charts, atrialfibrillation and sinus rhythm with a heart rate ≥90 bpm
were associated with a higher risk of mortality, as well as
low systolic blood pressure at hospital admission. Serum
creatinine levels between 0.8 and 1.1 mg/dL were
associated with a lower risk of mortality. The inclusion
of information from medical charts significantly
improved the discrimination of the model (AUC = 0.84
vs. 0.73, p < 0.001; LR χ2 = 122.41, p < 0.001) and its
goodness of fit (pseudo R2 = 0.22 vs. 0.08, AIC = 691.37
vs. 793.56). Figure 3 illustrates ROC curves for models #1
and #2.
Thirty-day readmission
Older age, longer hospital stay, a history of acute myo-
cardial infarction and low systolic blood pressure levels
at hospital admission were associated with a higher risk
of 30-day readmission, while gender was unrelated to
the outcome. The inclusion of systolic blood pressure
did not improve the discrimination (AUC = 0.65 vs. 0.63,
p = 0.08; LR χ2 = 7.91, p = 0.02) and the goodness of fit of
Table 2 Odds ratios (ORs) of 30-day mortality and readmission for each of the variables retained in multivariable risk-adjustment
models based on HDRs only (#1) and HDR plus clinical data (#2)
Characteristics Model #1 Model #2





Female 0.58 0.41–0.83 <0.01 0.63 0.37–1.06 0.08
Agea 1.00 1.00–1.00 <0.001 1.00 1.00–1.00 <0.001
Cerebrovascular disease
No 1.00 1.00
Yes 1.89 1.53–2.35 <0.001 1.96 1.33–2.87 <0.01
From medical charts
Systolic blood pressureb – 0.05 0.02–0.13 <0.001
Heart rhythm
Sinus rhythm with heart rate < 90 bpmc – 1.00
Sinus rhythm with heart rate≥ 90 bpmc – 2.94 1.87–4.61 <0.001
Atrial fibrillation – 1.78 1.31–2.41 <0.001
Pacemaker rhythm – 1.21 0.29–5.11 0.79





Female 0.95 0.66–1.36 0.78 0.96 0.67–1.38 0.82
Agea 1.00 1.00–1.00 <0.01 1.00 1.00–1.00 <0.01
Length of stayb 1.41 1.14–1.74 <0.01 1.38 1.12–1.71 <0.01
Previous acute myocardial infarction
No 1.00 1.00
Yes 2.05 1.11–3.78 0.02 1.90 1.05–3.44 0.03
From medical charts
Systolic blood pressureb – 0.33 0.19–0.59 <0.001
Abbreviations: CI confidence interval
aThis variable was cubed to achieve normality
bThis variable was log-transformed to achieve normality
cThis cutoff was chosen using ROC analysis to minimize the number of false positive and false negatives
dThis variable was transformed using the reciprocal of square root to achieve normality. We also included a squared term in the regression to achieve a good
model specification (OR = 357.41, 95 % CI = 36.36–3513.66, p < 0.001)
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862.86). Figure 4 illustrates ROC curves for models #1
and #2.
None of the data on filled prescriptions were retained
in the final risk-adjustment models of 30-day mortality
and readmission.
Discussion
In this large, comprehensive, regional study of patients
with HF across three hospitals, our results indicate thatadding specific clinical variables retrieved from medical
charts significantly contributed to the discrimination of
HDR-only models for 30-day mortality, but not for
30-day readmissions. These results confirm the findings
of other studies that highlighted the benefits of extract-
ing detailed information from medical records to
enhance the discrimination of models for 30-day mortality
[8, 10, 12, 14, 15, 24].
Consistent with previous studies [20, 25–34], we found
important clinical variables that were significantly associated
Fig. 2 Predicted probabilities of 30-day mortality and readmission for each of the continuous variables retained in the HDR-plus-clinical multivariable
risk-adjustment models
Lenzi et al. BMC Health Services Research  (2016) 16:473 Page 8 of 12with 30-day mortality. In particular, the predictors of mortal-
ity after hospital admission for HF included: atrial fibrilla-
tion, sinus rhythm with a heart rate ≥90 bpm, serum
creatinine, and low systolic blood pressure, which also was
associated with a higher risk of readmission. Atrial fibrilla-
tion is a common morbidity in HF and both conditions are
associated with poor outcomes [35] and cardiovascular
mortality [25]. Higher heart rate is a marker of poor cardiac
function and has been associated with increased risk of
mortality as an independent factor [36]. Values of serum
creatinine in the range 0.8 and 1.1 mg/dL, which represent
good renal function, were protective for 30-day mortality
after hospital admission for HF; on the contrary, alteration
of serum creatinine level (a marker of renal insufficiency) isoften related with HF because of common risk factors and
pathogenetic mechanism and is associated with an increas-
ing risk of morbidity and mortality [31, 37]. Lastly, low
systolic blood pressure is a marker of poor cardiac output in
HF and thus could identify a higher-risk patient [20]. These
results demonstrate that it may be useful to collect a
relatively small number of specified clinical variables from
medical charts that influence 30-day mortality following HF.
The risk-adjustment models for 30-day readmission
based on HDRs only and HDRs plus clinical data had a
lower discrimination than the mortality models, and
adding clinical data did not significantly improve the
model, as highlighted by other authors [6, 14]. This
result suggests that the data considered for this study,
Fig. 3 ROC curves for 30-day mortality models based on HDRs only (#1) and HDR plus clinical data (#2). Note: The ROC curve is a plot of sensitivity
versus 1 − specificity (often called the false-positive rate) that offers a summary of sensitivity and specificity across a range of cut points for a
continuous predictor. The area under the curve (AUC) ranges from 0.5 (no discrimination) to a theoretical maximum of 1 (perfect discrimination).
Abbreviations: ROC, receiver operation characteristic; Model #1 AUC, area under curve for model based on HDR variables; Model #2 AUC, area
under curve for model based on HDR plus OPD plus medical charts variables
Fig. 4 ROC curves for 30-day readmission models based on HDRs only (#1) and HDR plus clinical data (#2)
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predict this outcome. A systematic review found that
most of readmission risk prediction models, whether
designed for comparative or clinical purposes, perform
poorly, and suggested that factors associated with
readmission risk may differ according to the setting and
population being studied [38]. In our study, given that
differences in the case mix of the study patients were
not substantial, it is likely that the variables that we col-
lected did not describe sufficiently the patient’s clinical
complexity, or that the discrimination of the model for
readmissions depended only partially on characteristics
regarding patient’s severity and comorbidities. Hospital
readmissions may be influenced by other factors, such as
quality of care and organizational structure and
processes, that were not evaluated in this study [6, 38–40].
As an example, many studies have highlighted the effect-
iveness of multidisciplinary interventions pre and post
discharge on readmissions of patients with HF [2, 41–44].
In order to make readmission models clinically more
useful [15, 38], efforts are thus needed to identify variables
that may play an important role in predicting this
outcome.
An important finding from this study is that previous
drug prescriptions had no impact on either 30-day mor-
tality or readmission risk-adjustment models. This may
reflect the fact that comorbidities derived from HDRs
(either in the index hospitalization or in the previous
two years) were comprehensive, and data about drug
utilization reflecting the presence of these diseases did
not add relevant information to the models. However, a
recent study found that inpatient medications, such as
insulin, antipsychotics and other drugs with many
adverse effects, are associated with a higher risk of
30-day readmission [45]. This information demonstrates
that efforts to extract previous drug prescriptions may
not be warranted to increase the discrimination of
30-day readmission models for patients with HF, but that
data on drugs used during hospital care may substan-
tially enhance their predictive value.
The results of this study should be interpreted in light
of its strengths and limitations. This is the first study
conducted in Italy that evaluated the contribution of
clinical variables and data on drug prescriptions in risk-
adjustment models for HF quality of care. Moreover, we
investigated a very large number of clinical variables.
Limitations include, first, the potential lack of
generalizability to other settings; however, this study
included all patients from one of the largest Italian LHAs
and it is likely that our findings would be generalizable to
other regions or countries with a population composition
and healthcare delivery system similar to those of this
study. Second, data recording and accuracy might have
differed to some degree among the three hospitals understudy, thus affecting the reliability and validity of results.
Third, we did not consider some variables that have been
shown to be predictive of mortality and readmission
among patients with HF (e.g., body mass index, left
ventricular ejection fraction, brain natriuretic peptide, etc.)
[15] because they were scarcely reported in medical charts
and, when present, mostly measured after medical
interventions. Overall, the strengths of this study largely
outweigh the limitations.
Conclusions
In the present study we identified clinical data that signifi-
cantly improved the discrimination and goodness of fit of
a risk-adjustment model based on HDRs to predict 30-day
mortality following HF. Because the Italian Ministry of
Health has planned to enhance, by 2017, the HDRs Data-
base with the addition of clinical data for specific diseases
and procedures, our results identified three “candidate”
variables (i.e., systolic blood pressure, heart rhythm, and
serum creatinine) that might be easily included in the
HDRs to characterize the severity in patients with HF and
improve the prediction of 30-day mortality.
Further research is needed to understand the contribution
of some additional variables such as organizational and en-
vironmental factors, social support, substance abuse and
functional status, to predicting 30-day readmissions in pa-
tients with HF.
Additional files
Additional file 1: Description of data sources. (PDF 9 kb)
Additional file 2: List of comorbidities retrieved from the Hospital
Discharge Records Database. (PDF 16 kb)
Additional file 3: Primary data analyzed for this study. (XLS 901 kb)
Acknowledgements
The authors thank Silvio Candelori, MD, Emanuele Farolfi, MD, Enrica Perrone,
MD, and Tiziana Sanna, MD, from the University of Bologna for collecting
data from medical chart review. The authors would also like to thank Barbara
Bordoni, PhD, MD, from Bellaria Hospital; Aldo Pietro Maggioni, MD, from
ANMCO Research Center; and Adalgisa Protonotari, MD, from the LHA of
Bologna for their assistance in writing the paper and training medical
residents to abstract data from medical charts.
Funding
This study was not funded.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article (see Additional file 3).
Authors’ contributions
JL conceived the study, performed the statistical analysis, interpreted the results
and drafted the manuscript. VMA conceived the study, interpreted the results
and drafted the manuscript. TH interpreted the results and drafted the
manuscript. CD drafted the manuscript. IC performed the statistical analysis. SU
conceived the study and interpreted the results. GD conceived the study and
interpreted the results. PR interpreted the results and drafted the manuscript.
MPF conceived the study, interpreted the results and drafted the manuscript.
All authors read and approved the final manuscript.
Lenzi et al. BMC Health Services Research  (2016) 16:473 Page 11 of 12Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was exempt from notification to the Ethics Committee of the LHA
of Bologna because it consisted of a review of existing patients’ charts
(similarly to routine audit activities) and did not imply collection of additional
data from patients. All patients signed a consent form at hospital admission
for use of their data for administrative and research purposes, as is done
routinely to comply with the privacy law, and no further consent was
required. Data abstracted from medical charts were linked to HDRs and
encrypted at the Regional Health Information System Office. This encryption
eliminates the ability to trace the patient’s identity or other sensitive data.
None of the authors were involved in the treatment of the study patients
and had access to any identifying information before it was encrypted by
the Regional Health Information System Office.
The study was carried out in conformity with the regulations on data
management of the Regional Healthcare Authority of Emilia-Romagna, and
with the Italian “Code of conduct and professional practice applying to
processing of personal data for statistical and scientific purposes”
(Art. 20–21, DL 196/2003) (http://www.garanteprivacy.it/web/guest/home/
docweb/-/docwebdisplay/docweb/1115480) published in the Official Journal
no. 190 of
August 14, 2004) which explicitly exempts the need of ethical approval for
encrypted data (Preamble #8) collected for scientific and healthcare
purposes.
In Italy, anonymous administrative data-gathering is subject to the law
Protection of individuals and other subjects with regard to the processing of
personal data, ACT no. 675 of 31.12.1996 (amended by Legislative Decree no.
123 of 09.05.1997, no. 255 of 28.07.1997, no. 135 of 08.05.1998, no. 171 of
13.05.1998, no. 389 of 6.11.1998, no. 51 of 26.02.1999, no. 135 of 11.05.1999,
no. 281 of 30.07.1999, no. 282 of 30.07.1999 and no. 467 of 28.12.2001)
(http://www.privacy.it/legge675encoord.html).
Author details
1Department of Biomedical and Neuromotor Sciences, Alma Mater
Studiorum – University of Bologna, via San Giacomo 12, 40126 Bologna, Italy.
2Department of Surgery, Stanford University, 300 Pasteur Drive, Stanford, CA
94305-2200, USA. 3Department of Clinical Governance, Bologna Local
Healthcare Authority, via Castiglione 29, 40124 Bologna, Italy. 4Department of
Programming and Control, Bologna Local Healthcare Authority, via
Castiglione 29, 40124 Bologna, Italy. 5Department of Cardiology, Bellaria
Hospital, via Altura 3, 40139 Bologna, Italy. 6Department of Cardiology,
Maggiore Hospital, Largo Nigrisoli 2, 40133 Bologna, Italy.
Received: 25 November 2015 Accepted: 31 August 2016
References
1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K,
et al. ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute
and Chronic Heart Failure 2012 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association of the ESC
(HFA). Eur J Heart Fail. 2012;14:803–69.
2. Takeda A, Taylor SJC, Taylor RS, Khan F, Krum H, Underwood M. Clinical service
organisation for heart failure. Cochrane Database Syst Rev. 2012;9:CD002752.
3. Groene O, Skau JK, Frølich A. An international review of projects on hospital
performance assessment. Int J Qual Health Care. 2008;20:162–71.
4. Sasaki N, Lee J, Park S, Umegaki T, Kunisawa S, Otsubo T, et al. Development
and validation of an acute heart failure-specific mortality predictive model
based on administrative data. Can J Cardiol. 2013;29:1055–61.
5. Krumholz HM, Wang Y, Mattera JA, Wang Y, Han LF, Ingber MJ, et al. An
administrative claims model suitable for profiling hospital performance
based on 30-day mortality rates among patients with heart failure.
Circulation. 2006;113:1693–701.
6. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, et al. An
administrative claims measure suitable for profiling hospital performance onthe basis of 30-day all-cause readmission rates among patients with heart
failure. Circ Cardiovasc Qual Outcomes. 2008;1:29–37.
7. Johnston TC, Coory MD, Scott I, Duckett S. Should we add clinical variables
to administrative data?: The case of risk-adjusted case fatality rates after
admission for acute myocardial infarction. Med Care. 2007;45:1180–5.
8. Pine M, Jordan HS, Elixhauser A, Fry DE, Hoaglin DC, Jones B, et al.
Enhancement of claims data to improve risk adjustment of hospital
mortality. JAMA. 2007;297:71–6.
9. Agenzia Nazionale per i Servizi Sanitari Regionali (Agenas). Programma
Nazionale Esiti. 2014. http://95.110.213.190/PNEed14_EN/index.php.
Accessed 13 Nov 2015.
10. Tabak YP, Johannes RS, Silber JH. Using automated clinical data for risk
adjustment: development and validation of six disease-specific mortality
predictive models for pay-for-performance. Med Care. 2007;45:789–805.
11. Escobar GJ, Greene JD, Scheirer P, Gardner MN, Draper D, Kipnis P.
Risk-adjusting hospital inpatient mortality using automated inpatient,
outpatient, and laboratory databases. Med Care. 2008;46:232–9.
12. Tabak YP, Sun X, Derby KG, Kurtz SG, Johannes RS. Development and
validation of a disease-specific risk adjustment system using automated
clinical data. Health Serv Res. 2010;45:1815–35.
13. Colais P, Di Martino M, Fusco D, Davoli M, Aylin P, Perucci CA. Using clinical
variables and drug prescription data to control for confounding in outcome
comparisons between hospitals. BMC Health Serv Res. 2014;14:495.
14. Hammill BG, Curtis LH, Fonarow GC, Heidenreich PA, Yancy CW, Peterson
ED, et al. Incremental value of clinical data beyond claims data in predicting
30-day outcomes after heart failure hospitalization. Circ Cardiovasc Qual
Outcomes. 2011;4:60–7.
15. Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, et al. Risk
prediction in patients with heart failure: a systematic review and analysis.
JACC: Heart Failure. 2014;2:440–6.
16. Fonarow GC, Adams Jr KF, Abraham WT, Yancy CW, Boscardin WJ. Risk
stratification for in-hospital mortality in acutely decompensated heart
failure: classification and regression tree analysis. JAMA. 2005;293:572–80.
17. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al.
The Seattle heart failure model: prediction of survival in heart failure.
Circulation. 2006;113:1424–33.
18. Fabbri G, Gorini M, Maggioni AP. IN-CHF: il registro italiano dello
scompenso cardiaco. Dieci anni di esperienza. G Ital Cardiol. 2006;7:689–94.
19. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M,
et al. Incident heart failure prediction in the elderly: the health ABC heart
failure score. Circ Heart Fail. 2008;1:125–33.
20. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W,
Gheorghiade M, et al. Predictors of mortality after discharge in patients
hospitalized with heart failure: An analysis from the Organized Program to
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF). Am Heart J. 2008;156:662–73.
21. Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED,
et al. A validated risk score for in-hospital mortality in patients with heart
failure from the American Heart Association get with the guidelines
program. Circ Cardiovasc Qual Outcomes. 2010;3:25–32.
22. Hilbe JM. Logistic Regression Models. Boca Ratona: Chapman & Hall/CRC
Press; 2009.
23. Seshan VE, Gönen M, Begg CB. Comparing ROC curves derived from
regression models. Stat Med. 2013;32:1483–93.
24. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M,
Greenberg BH, et al. Predictors of in-hospital mortality in patients
hospitalized for heart failure: insights from the Organized Program to
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347–56.
25. Bajaj NS, Bhatia V, Sanam K, Ather S, Hashim T, Morgan C, et al. Impact of
atrial fibrillation and heart failure, independent of each other and in
combination, on mortality in community-dwelling older adults. Am J
Cardiol. 2014;114:909–13.
26. Eapen ZJ, Greiner MA, Fonarow GC, Yuan Z, Mills RM, Hernandez AF, et al.
Associations between atrial fibrillation and early outcomes of patients with
heart failure and reduced or preserved ejection fraction. Am Heart J.
2014;167:369–75.
27. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship
and prognostic significance of atrial fibrillation in heart failure patients with
preserved ejection fraction: a community-based study. Circulation.
2013;128:1085–93.
Lenzi et al. BMC Health Services Research  (2016) 16:473 Page 12 of 1228. Bui AL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Yancy CV, Bhatt DL,
et al. Admission heart rate and in-hospital outcomes in patients hospitalized
for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J.
2013;165:567–74.
29. Habal MV, Liu PP, Austin PC, Ross HJ, Newton GE, Wang X, et al. Association
of heart rate at hospital discharge with mortality and hospitalizations in
patients with heart failure. Circ Heart Fail. 2014;7:12–20.
30. Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, Ghio S, et al.
Predictors of clinical outcomes in elderly patients with heart failure. Eur J
Heart Fail. 2011;13:528–36.
31. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the
kidney in heart failure. Eur Heart J. 2012;33:2135–43.
32. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M,
Greenberg B, et al. Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
Am Heart J. 2004;148:43–51.
33. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She
L, et al. Systolic blood pressure at admission, clinical characteristics, and
outcomes in patients hospitalized with acute heart failure. JAMA.
2006;296:2217–26.
34. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, Laskar S, Smith AL,
Dunbar S, et al. Hospitalization epidemic in patients with heart failure: risk
factors, risk prediction, knowledge gaps, and future directions. J Card Fail.
2011;17:54–75.
35. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal
relations of atrial fibrillation and congestive heart failure and their joint
influence on mortality: the Framingham Heart Study. Circulation.
2003;107:2920–5.
36. Kannel WB, Kannel C, Paffenbarger Jr RS, Cupples LA. Heart rate and
cardiovascular mortality: the Framingham Study. Am Heart J.
1987;113:1489–94.
37. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and
heart failure. Prognostic and therapeutic implications from a prospective
cohort study. Circulation. 2004;109:1004–9.
38. Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M,
et al. Risk prediction models for hospital readmission: a systematic review.
JAMA. 2011;306:1688–98.
39. Amarasingham R, Moore BJ, Tabak YP, Drazner MH, Clark CA, Zhang S, et al.
An automated model to identify heart failure patients at risk for 30-day
readmission or death using electronic medical record data. Med Care.
2010;48:981–8.
40. Horwitz LI, Wang Y, Desai MM, Curry LA, Bradley EH, Drye EE, et al.
Correlations among risk-standardized mortality rates and among risk-
standardized readmission rates within hospitals. J Hosp Med. 2012;7:690–6.
41. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A
multidisciplinary intervention to prevent the readmission of elderly patients
with congestive heart failure. N Engl J Med. 1995;333:1190–5.
42. Garin N, Carballo S, Gerstel E, Lerch R, Meyer P, Zare M, et al. Inclusion into
a heart failure critical pathway reduces the risk of death or readmission after
hospital discharge. Eur J Intern Med. 2012;23:760–4.
43. Bradley EH, Curry L, Horwitz LI, Sipsma H, Wang Y, Walsh MN, et al. Hospital
strategies associated with 30-day readmission rates for patients with heart
failure. Circ Cardiovasc Qual Outcomes. 2013;6:444–50.
44. Avaldi VM, Lenzi J, Castaldini I, Urbinati S, Di Pasquale G, Morini M, et al.
Hospital readmissions of patients with heart failure: the impact of hospital
and primary care organizational factors in northern Italy. PLoS One.
2015;10:e0127796.
45. Cronin PR, Greenwald JL, Crevensten GC, Chueh HC, Zai AH. Development
and implementation of a real-time 30-day readmission predictive model.
AMIA Annu Symp Proc. 2014;2014:424–31.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
